Earnings ·
20/20 Biolabs reported second quarter 2026 financial results with total revenue increasing 36.5% to $0.7 million and…
AIDX20/20 Biolabs, Inc.
20/20 Biolabs reported second quarter 2026 financial results with total revenue increasing 36.5% to $0.7 million and gross profit rising 86.6% to $0.3 million, driven by a 47.1% year-over-year increase in OneTest™ revenue to $0.7 million. Gross margin expanded to 41.7% from 30.5%, while the net loss widened to $1.5 million due to operating expenses and non-cash charges. The company strengthened its balance sheet by raising $6.0 million in Series E preferred financing during the first half of 2026 and eliminating all convertible note debt through conversion into preferred stock. Cash reserves grew to $4.5 million as of June 30, 2026. Additionally, the company entered a standstill agreement with Streeterville regarding potential conversions of its Series E shares. The company operates in the healthcare diagnostics industry, developing AI-powered blood tests for early cancer detection.